Orphazyme is a late-stage biopharmaceutical company harnessing the amplification of Heat Shock Proteins, or HSPs, in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative rare diseases. Co.'s product candidate, arimoclomol is an orally- or naso/gastrically-administered small molecule that crosses the blood-brain barrier and is designed to selectively amplify the natural role of endogenous HSPs, which protect against cellular toxicity caused by protein misfolding, aggregation and lysosomal dysfunction. Co. is also developing arimoclomol for the treatment of neurological manifestations of Gaucher disease. We show 1 historical shares outstanding datapoints in our ORPH shares outstanding history coverage, used to compute ORPH market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ORPH market cap history over the course of time is important for investors
interested in comparing ORPH's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ORPH versus a peer is one thing; comparing
ORPH market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ORPH can fluctuate over the course of history.
With this page we aim to empower investors researching ORPH by allowing them to research the ORPH market cap history. |
Free ORPH Email Alerts:
Video: The Importance of Market Cap
